Introduction: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D). This study aimed to estimate the distribution of 10-year predicted CVD risk among newly diagnosed T2D patients, using China-PAR (Prediction for Atherosclerotic cardiovascular disease Risk in China) model, in the NEW2D population.
Methods: CVD was defined as the first occurrence of acute myocardial infarction, stroke, or death from cardiovascular causes. Risk factors included in the China-PAR model were age, geographic region, urbanization, smoking, waist circumference, systolic blood pressure, total cholesterol, HDL-C, and family history of CVD.
Results: Of the total population of 5770 patients, 2301 fulfilled the inclusion criteria (e.g., no glucose-lowering therapy) and were included in the current analyses. The model-predicted mean CVD risk was 7.4%, with 54% of patients having a medium or high risk to develop CVD within 10 years (Table 1).
Conclusions: Our study demonstrates that the majority of newly diagnosed patients with T2D in China have a medium or high risk to develop CVD. SBP appears to be a prominent driver of this elevated risk. These results underscore the importance of primary prevention and management of CVD in patients with T2D.
Y. Yan: Employee; Self; Eli Lilly and Company. X. Cai: None. J. Xu: None. D. Manner: Employee; Self; Eli Lilly and Company. J.P. Bae: Employee; Self; Eli Lilly and Company. R.J. Heine: Employee; Self; Eli Lilly and Company. L. Ji: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck KGaA, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk A/S, Roche Pharma, Sanofi, Takeda Pharmaceutical Company Limited. Research Support; Self; AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Roche Pharma, Sanofi.
